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Abstract
Tumor-targeting Salmonella enterica serovar Typhimurium A1-R (Salmonella A1-R) had
strong efficacy on a melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse
model. GFP-expressing Salmonella A1-R highly and selectively colonized the PDOX mela-
noma and significantly suppressed tumor growth (p = 0.021). The combination of Salmo-
nella A1-R and cisplatinum (CDDP), both at low-dose, also significantly suppressed the
growth of the melanoma PDOX (P = 0.001). Salmonella A1-R has future clinical potential for
combination chemotherapy with CDDP of melanoma, a highly-recalcitrant cancer.
Introduction
Melanoma is a recalcitrant cancer. When melanoma metastasizes to regional lymph nodes, the
5-year survival rate is 29% and when it metastasizes to organs, the survival rate is 7% [1].
Although recently-developed immunotherapy has extended survival to some extent, the 5-year
survival rates have not been significantly increased [2]. Decarbazine and cisplatinum have been
used to treat melanoma with limited efficacy [3, 4]. Therefore, more effective approaches to
melanoma treatment are needed.
Immunotherapy involving PD-1/PD-L1 blockade has had some success with melanoma but
is limited by lack of sufficient tumor infilation of activated lymphocytes to kill the cancer cells
within the tumor in the majority of patients tested [5].
Tumor-targeting Salmonella A1-R developed by our laboratory is auxotrophic (leucine-
arginine dependent) which prevents it from continuously infecting normal tissues. Monother-
apy using Salmonella A1-R was able to regress or eliminate primary and/or metastatic tumors
in models of mouse highly aggressive of prostate [6, 7], breast [8–10], lung [11, 12], pancreatic
[13–17], ovarian [18, 19], stomach [20], and cervical cancer [21], as well as sarcoma [22–26]
and glioma [27, 28].
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Patient-derived orthotopic xenograft (PDOX) models were developed by our laboratory
[29, 30]. In the PDOX models, the patient’s tumor is transplanted in the organ of nude or other
immunocompetent mice corresponding to its origin and thereby metastasizes such that the
tumor mimics the complexity of tumor behavior in patients. Our laboratory has developed
PDOX models of all major tumor types including colon [29], pancreatic [31], breast [32], ovar-
ian [33], lung [34], cervical [21], stomach cancer [35], as well as mesothelioma [36] and sar-
coma [25, 26, 37, 38].
The aim of the current study was to determine the efficacy of Salmonella A1-R on a PDOX
model of melanoma compared to and in combination with standard chemotherapy.
Materials and Methods
Animal Experiments and Ethics Statement
All animal studies were conducted with an AntiCancer Institutional Animal Care and Use
Committee (IACUC) protocol specifically approved for this study and in accordance with the
principles and procedures outlined in the National Institutes of Health Guide for the Care and
Use of Animals under Assurance Number A3873-1. Athymic nu/nu nude mice (AntiCancer,
Inc., San Diego, CA), 4–6 weeks old, were used in this study. Animals were housed in a barrier
facility on a high-efficiency particulate arrestance (HEPA)-filtered rack under standard condi-
tions of 12-hour light/dark cycles. The animals were fed an autoclaved laboratory rodent diet
(S1 File). In order to minimize any suffering of the animals, anesthesia and analgesics were
treated for all surgical procedures. Animals were anesthetized by subcutaneous (s.c.) injection
of a 0.02 ml solution of 20 mg/kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg acepromazine
maleate. The response of animals during surgery was monitored to ensure adequate depth of
anesthesia. Ibuprofen (7.5 mg/kg orally in drinking water every 24 hours for 3 days post-sur-
gery) was used in order to provide analgesia post-operatively in the surgically-treated animals.
The animals were carefully observed on a daily basis and would be humanely sacrificed by CO2
inhalation if they met the following humane endpoint criteria: prostration, skin lesions, signifi-
cant bodyweight loss, difficulty breathing, epistaxis, and rotational motion. Individual cages
housed animals only in the same treatment group with no more than five mice per cage.
Melanoma Specimen Collection
The patient had given written informed consent for experimental research on residual tumor
tissue available after histopathologic and cytogenetic analyses. The written informed consent
document was recorded in a special binder for such documents. The consent procedure was
approved by the Institutional Review Board of the UC San Diego Medical Center. This study
was also conducted under the approval of the UCSD IRB.
Patient-Derived Orthotopic Xenograft (PDOX) Melanoma Model
Tumor tissue was obtained from a patient at the time of surgery at the UCSDMedical Center.
The harvested tumor was cut into fragments (3-mm3) and transplanted into the back skin of
five nude mice with two mice transplanted with two tumors. Animals were sacrificed at the
end of the experiment. Tumors were harvested and fragments were transplanted to one or two
sides of the back skin for the next passage and/or for analysis.
Histology
Four tumors were harvested from four mice. Harvested tumor samples were fixed with 10%
formalin solution, embedded into paraffin and sectioned. Hematoxylin and eosin (H&E)
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staining was performed with standard protocol. For immunohistochemistry, paraffin-embed-
ded tumor sections were stained with a rabbit anti-human MHC class I antibody (1:100;
ab52922, Abcam, Cambridge, MA) and a mouse anti-MHC class I H2 Kd + H2 Dd antibody
(1:100; ab24229, Abcam). Immunohistochemistry was performed using anti-rabbit and anti-
mouse secondary antibodies and avidin/biotin/horseradish peroxidase complex (Dako Den-
mark A/S, Glostrup, Denmark) and developed with the DAB kit (BD Biosciences, San Diego,
CA) [16]. Five microscopic fields were inspected for each tumor.
Salmonella A1-R and Chemotherapy Drugs
Green fluorescent protein (GFP)-expressing Salmonella A1-R bacteria were grown overnight
in LB medium and then diluted in 1:10 with LB medium. Bacteria were harvested at late-log
phase, washed with phosphate buffered saline (PBS), and diluted in PBS [6–8]. Two weeks
after transplantation, bacteria and/or chemotherapy were started. 5-fluorouracil (5-FU, Kyowa
Hakko Kirin, Co., Tokyo, Japan) and cisplatinum (CDDP, Nippon Kayaku, Co., Tokyo, Japan)
solutions were administered via intraperitoneal (i.p.) injection at a dose of 10 mg/kg (5-FU)
and 3 or 5 mg/kg (CDDP) once a week. Salmonella A1-R was injected intravenously (i.v.) at a
dose of 3 or 5 × 107 CFU/body once a week. The approximate volume of the mass was mea-
sured with a caliper twice a week and calculated with the following formula: Tumor volume = 4/
3π × (d/2)2 × D/2, where d is the minor tumor axis and D is the major tumor axis. Treatment
efficacy was indicated as a ratio of the tumor volume at each time point compared with the
tumor volume at the beginning of the treatment. Body weight of the mice was measured on a
balance twice a week.
Detection of GFP-Labeled Salmonella A1-R Bacteria in Tumor and
Organs
Two days before harvesting tumors and normal organs, mice were injected intravenously with
Salmonella A1-R (5 × 107 CFU/body). Two days later, PDOX tissues from melanoma tumor
and normal organs (liver, spleen and blood) were harvested and weighed. The tumor and
organs were minced and diluted in 1:1, 1:10 and 1:100 with 100 μl PBS, respectively. Each dilu-
tion (10 μl) was spotted on an LB agar plate containing 50 μg/mL ampicillin and the plates
were incubated at 37°C for 24 hours. Relative colony numbers are calculated by actual colony
number divided by mg of tissue. One tumor and normal organs from one mouse were har-
vested and the experiment was repeated three times.
Imaging
The iBox Imaging System (UVP LLC, Upland, CA) was used for imaging GFP-labeled S. typhi-
murium A1-R [39–42]. The BHS System Microscope (Olympus) was used for H&E staining
and immunohistochemistry.
Fig 1. Establishment of a melanoma patient-derived orthotopic xenograft (PDOX) model. A) Schematic diagram of the
experimental protocol.B) Representative cross-sections of transplanted tumor 28 days after transplantation obtained from an
orthotopically-transplanted patient’s melanoma. Scale bar: 10 mm. C) Immunohistochemical characterization of PDOXmelanoma after
being grown in nude mice. H&E-stained sections (left column) and immunohistochemistry for human MHC class I (HLA; middle column)
and mouse MHC class I (H2 KdtH2 Dd; right column). Strong staining for HLA was observed in the cancer cells (middle column), whereas
strong staining for H2 KdtH2 Dd was observed in the stromal cells (right column). Magnified views of boxed region in the upper rows are
indicated at the middle rows and magnified views of boxed region in the middle rows are indicated in the lower rows. Black arrowhead
indicates necrotic region of the tumor. Scale bars: (top and middle row) 200 μm; (bottom row) 100 μm.
doi:10.1371/journal.pone.0160882.g001
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Statistical Analysis
STATA 12.0 SE was used for further data analysis. Time points were chosen a priori: 28 days
was selected as a final end point, and 10 days was chosen as a midway representative time
point. However, data were collected from 9 time points throughout the 28 days, at regular
intervals. A repeated-measures regression model was used to assess the tumor volume of the
animals over these regular intervals. The within-subject covariance structure of the data was
compound symmetric, therefore we proceeded with repeated measure ANOVA including the
repeated option to compute p-values for conservative F-tests. Greenhouse-Geisser correction
was performed to correct for any violations of sphericity. The treatment-by-time interaction
was significant (p = 0.0000) as were the main-effects for treatment and time (p = 0.0000) for
Salmonella A1-R, CDDP and Salmonella A1-R and CDDP combined. The specific compari-
sons of interest remained significant within this model. Graph of adjusted predictions of inter-
action of treatment group and time with 95%CI and graph of mean change in tumor volume
over time.
Results
Patient-Derived Melanoma Growing Orthotopically in Nude Mice
Four weeks after transplantation of the patient melanoma, solid tumors were found growing in
the back skin of the nude mice. The tumors were harvested from the mice and used for the
next passage and histological analysis (Fig 1A).
To determine whether the grown tumor is completely derived from melanoma patients’
specimen, immunohistochemistry analysis was performed. The melanoma PDOX strongly
expressed human MHC class I protein (Fig 1C), whereas cells around blood vessels or stromal
cells only reacted with mouse MHC class I antibody (Fig 1C). These data indicate that the
growing PDOX tumor was human.
Salmonella A1-R is Highly Effective on the PDOXMelanoma in Nude
Mice
Salmonella A1-R was administrated intravenously to the melanoma PDOX two weeks after
transplantation at a dose of 5 × 107 CFU/body, qW×4. The relative tumor volume on day-28,
compared to day-0, of untreated control was 8.46 ± 1.95 and in the Salmonella A1-R-treated
mice, the tumor volume ratio was 1.68 ± 0.37 (p = 0.021) (Fig 2B). There were five mice in each
group and the experiment was repeated twice.
Extensive GFP-labeled Salmonella A1-R could be isolated from the tumor and could not be
isolated from the blood and spleen and only very small amounts could be isolated from the
liver (Fig 2C and 2D). These results indicated that Salmonella A1-R selectively and effectively
colonized and targeted the tumor.
Fig 2. Salmonella A1-R targeting and efficacy on the melanoma PDOXmodel. A) Schematic diagram of the experimental protocol. B)
Efficacy of Salmonella A1-R is indicated by the volume ratio of the transplanted tumor at day 28 after injection compared with the tumor at the
beginning of the treatment. Tumor size of the Salmonella A1-R-treated group was significantly decreased compared with the untreated control
group. The values are mean relative tumor volume ± SEM (bars). There were five mice per group. *p < 0.05 compared to the untreated group.C)
Distribution of GFP-labeled Salmonella A1-R in tumor and organs. Representative images of GFP-labeled Salmonella A1-R bacteria isolated
and cultured from the tumor and the normal organs (blood, liver and spleen) of the mice treated with Salmonella A1-R. Fluorescence imaging
with the iBox small animal imaging system (UVP LLC). Scale bar: 10 mm. D)Colony number of each sample is indicated per mg of harvested
tissue. Tissues were collected from three different mice. GFP-labeled Salmonella A1-R was clearly detected in the tumor. A small number of
GFP-labeled Salmonella A1-R was detected in the liver and no GFP-labeled Salmonella A1-R was detected in blood and spleen.
doi:10.1371/journal.pone.0160882.g002
Efficacy of Salmonella A1-R on a Melanoma PDOX
PLOSONE | DOI:10.1371/journal.pone.0160882 August 8, 2016 6 / 12
Efficacy of Salmonella A1-R on a Melanoma PDOX
PLOSONE | DOI:10.1371/journal.pone.0160882 August 8, 2016 7 / 12
Efficacy of Salmonella A1-R and Chemotherapy on the PDOX
Melanoma
Two weeks after tumor transplantation, mice were treated with the following groups: (1)
untreated control (Control); (2) 5-fluorouracil (5-FU; 10 mg/kg, i.p., qW×4); (3) cisplatinum
(CDDP; 5 mg/kg, i.p., qW×4); (4) Salmonella A1-R (5 × 107 CFU/body, i.v., qW×4) and (5)
Salmonella A1-R (3 × 107 CFU/body, i.v., qW×4) + CDDP (CDDP, 3 mg/kg, i.p., qW×4)
(Fig 3A).
The relative tumor volume on day 28, compared with day 0, of each group was as follows:
(1) untreated control: 9.63 ± 1.37; (2) 5-FU: 6.86 ± 0.52; (3) CDDP: 2.25 + 0.32 (p = 0.0001);
(4) Salmonella A1-R: 2.29 ± 0.35 (p = 0.0001); (5) Salmonella A1-R + CDDP: 2.90 ± 0.47. The
treatment-by-time interaction was significant (p = 0.0000) as were the main-effects for treat-
ment and time (p = 0.0000) for Salmonella A1-R, CDDP and Salmonella A1-R and CDDP
combined. These data suggest that Salmonella A1-R and/or CDDP treatment is highly effective
in the melanoma PDOX and the efficacy appears from the very early period of the treatment
(Fig 3). Regarding the choice of chemotherapy drugs, CDDP was used as a positive control and
5-FU as a negative control in addition to the untreated control, since 5-FU is known not to be
effective against melanoma [43].
The relative body weight on day 28 compared with day 0, of each group was as follows: (1)
untreated control: 1.13 ± 0.012; (2) 5-FU: 1.12 ± 0.016; (3) CDDP: 1.02 ± 0.033; (4) Salmonella
A1-R: 1.07 ± 0.032 and (5) Salmonella A1-R + CDDP: 1.07 ± 0.022. Only the body weight of
CDDP-treated mice was significantly decreased compared with untreated control (p = 0.0001)
at the end of this experiment (Fig 3C).
Discussion
Salmonella has been previously used for effective cancer therapy of a melanoma and other cell
lines [44–58]. The Salmonella strain (VNP20009) was attenuated by a lipid A–mutation
(msbB), purine auxotrophy (purI) and amino acid auxotrophy [44]. VNP20009 was safely
administered to patients in a Phase I clinical trial on patients with metastatic melanoma. How-
ever it was poorly colonized in the tumors since it might be over-attenuated [58]. Our results
are the first to demonstrate efficacy of Salmonella treatment on a patient melanoma tumor
models (PDOX).
Salmonella A1-R was also previously shown to be active in syngeneic mouse tumor models:
we recently determined the efficacy of Salmonella A1-R on the Lewis lung (LLC) in C57BL/6
(C57) immunocompetent mice and observed anti-metastatic efficacy [59] as well as against pri-
mary tumors [60]. These results suggest that Salmonella A1-R is also active in animals with an
intact immune system and a syngeneic rather than xenografted tumor. The present and
Fig 3. Effect of a tumor-targeting Salmonella A1-R and chemotherapy on the melanoma PDOX. A)
Schematic diagram of the experimental protocol. (1) untreated control (Control); (2) 5-fluorouracil (5-FU; 10
mg/kg, intraperitoneal injection (i.p.), qW×4); (3) cisplatinum (CDDP; 5 mg/kg, i.p., qW×4); (4) Salmonella
A1-R (5 × 107 CFU/body, intravenously (i.v.), qW×4) and (5) Salmonella A1-R (3 × 107 CFU/body, i.v., qW×4)
+ CDDP (CDDP; 3 mg/kg, i.p., qW×4).B)Growth curves of the melanoma PDOX tumor treated with various
drugs as described above. B1: Mean change in tumor volume plotted against time; Control, n = 9; 5-FU, n = 4;
CDDP, n = 5; Salmonella A1-R, n = 9; Salmonella A1-R + CDDP, n = 8. B-2: Data plotted are linear prediction
versus time with adjusted predictions of interaction of treatment group and time with 95% Cis. The treatment-
by-time interaction was significant (p = 0.0000) as were the main-effects for treatment and time (p = 0.0000)
for Salmonella A1-R, CDDP and Salmonella A1-R and CDDP combined. C)Comparison of body weight of
nude mice transplanted PDOX tumors after Salmonella A1-R and/or chemotherapy. All values represent
mean ± SEM; Control, n = 8; 5-FU, n = 4; CDDP, n = 4; Salmonella A1-R, n = 7; Salmonella A1-R + CDDP,
n = 4. **p < 0.01, compared with the untreated control group.
doi:10.1371/journal.pone.0160882.g003
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previous results suggest the potential of Salmonella A1-R alone or in combination with CDDP
to treat melanoma patients in the future.
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